Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.
Stage IV Nasopharyngeal Carcinoma
DRUG: cisplatin and 5-Fu combined with nimotuzumab
Objective response rate, To be determined by measurement of target lesions according to RECIST criteria, study period of 19 Months|Progression free survival, Defined as the time in months from first dose of Nimotuzumab until PD is observed or death occurs due to any cause., 19 Months
Overall survival, Defined as the time in months from first dose of Nimotuzumab to the date of death is observed or to last follow-up visit., 19 Months|Quality of life, Using EORTC QLQ-C30(version 3.0) and EORTC QLQ-H\&N35(Version 1.0) to access the quality of life. Collecting data before treatment, 1 week after each 2 cycles of chemotherapy, 1 months after all treatment finished., 8 Months
This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.